DK1849470T3 - Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor - Google Patents
Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor Download PDFInfo
- Publication number
- DK1849470T3 DK1849470T3 DK06712292.9T DK06712292T DK1849470T3 DK 1849470 T3 DK1849470 T3 DK 1849470T3 DK 06712292 T DK06712292 T DK 06712292T DK 1849470 T3 DK1849470 T3 DK 1849470T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- drug
- dose
- day
- ftd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Mosteller-formlen fif. N. Enal. J. Med. 1987 Oct 22; 317 (17): 1098 (letter))
1. Terapeutisk cancerlægemiddel, som er en sammensætning omfattende α,α,α-trifluorthymidin (FTD) og 5-chlor-6-(1-(2-iminopyrrolidinyl)methyl)uracil-hydrochlorid i et molforhold på 1 : 0,5, til anvendelse ved behandling af cancer hos en patient, der er et menneske, med behov herfor ved oral indgivelse af lægemidlet i en dosis, som en dosis af FTD, på 20 til 80 mg/m2/dag, to gange dagligt.
2. DuBois og DuBois-formlen (jf. Arch. Int. Med. 1916 17: 863-71; J. Clin. Anesth. 1992; 4 (1): 4-10) (a) legemsoverflade (m2)= 0,20247 x højde (m)0,725 x vægt (kg)0 425 (b) legemsoverflade (m2)= 0,007184 x højde (cm)0,725 x vægt (kg)0,425
2. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives oralt til en patient med behov herfor i en dosis, som en dosis af FTD, på 25 til 75 mg/m2/dag, indgivet to gange dagligt.
3. Haycock-formlen (jf. The Journal of Pediatrics 1978 93: 1: 62-66)
3. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives to gange dagligt i henhold til en ugebaseret plan, der indbefatter indgivelse i fem dage og to dages pause.
4. Gehan and George-formlen (jf. Cancer Chemother. Rep. 1970 54: 225-35)
4. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives på en sådan måde, at en ugentlig doseringscyklus bestående af indgivelse i fem dage og to dages pause udføres i to uger, efterfulgt af pause i to uger.
5. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1, hvor lægemidlet indgives til en patient med behov herfor i en dosis, som en dosis af FTD, på FTD, på 50 til 70 mg/m2/dag.
6. Terapeutisk cancerlægemiddel til anvendelse ifølge krav 1 til 5, hvor lægemidlet indgives til en patient med behov herfor i en dosis, som en dosis af FTD, på 70 mg/m2/dag.
7. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor den cancer, som det terapeutiske cancerlægemiddel anvendes mod, indbefatter øsofaguxcancer, gastrisk cancer, levercancer, galdeblære-/galdevejscancer, pancreascancer, kolorektal cancer, hoved- og halscancer, lungecancer, brystcancer, cervixcancer, ovariecancer, blærecancer, prostatacancer, testikeltumor, bløddels- og knoglesarkom, hudcancer, malignt lymfom, leukæmi og hjernetumor.
8. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor den cancer, som det terapeutiske cancerlægemiddel anvendes mod, indbefatter maligne solide cancere udvalgt blandt gastrisk cancer, pancreascancer, brystcancer, kolorektal cancer, hoved- og halscancer, galdeblære-/galdevejscancer og lungecancer.
9. Terapeutisk cancerlægemiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor dosen af sammensætningen, der indgives til en patient med behov herfor, bestemmes på basis af patientens legemsoverflade, hvilken legemsoverflade beregnes ved anvendelse af en hvilken som helst af de følgende beregningsformler 1 til 5:
5. Bovd-formlen (if. Minneaoolis: Universitv of Minnesota Press. 19351
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1849470T3 true DK1849470T3 (da) | 2017-08-14 |
| DK1849470T4 DK1849470T4 (en) | 2024-04-02 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06712292.9T DK1849470T4 (en) | 2005-01-26 | 2006-01-25 | Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (da) |
| JP (1) | JP5576591B2 (da) |
| KR (1) | KR101468216B1 (da) |
| AU (1) | AU2006209547C1 (da) |
| BE (1) | BE2017C028I2 (da) |
| CA (1) | CA2594713A1 (da) |
| CY (2) | CY1119393T1 (da) |
| DK (1) | DK1849470T4 (da) |
| ES (1) | ES2630002T5 (da) |
| FI (1) | FI1849470T4 (da) |
| FR (1) | FR17C1028I2 (da) |
| HU (2) | HUE033306T2 (da) |
| LT (2) | LT1849470T (da) |
| LU (1) | LUC00036I2 (da) |
| NL (1) | NL300889I2 (da) |
| PL (1) | PL1849470T5 (da) |
| PT (1) | PT1849470T (da) |
| SI (1) | SI1849470T2 (da) |
| TW (1) | TWI362265B (da) |
| WO (1) | WO2006080327A1 (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| ES2630002T5 (es) | 2005-01-26 | 2024-09-19 | Taiho Pharmaceutical Co Ltd | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| ES2587381T3 (es) | 2007-04-25 | 2016-10-24 | Cyclacel Limited | Uso de sapacitabina para tratar una enfermedad proliferativa |
| KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
| AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
| JP2011520845A (ja) * | 2008-05-15 | 2011-07-21 | カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー | 抗癌剤の組合せによる治療 |
| WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
| TWI473628B (zh) | 2009-07-22 | 2015-02-21 | 用於對氧化敏感之類鴉片藥劑之抗破壞劑型 | |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| AU2012289764B2 (en) | 2011-07-29 | 2017-03-02 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| ES2648129T3 (es) | 2011-07-29 | 2017-12-28 | Grünenthal GmbH | Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento |
| HUE035347T2 (en) | 2011-08-16 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| PL2838512T3 (pl) | 2012-04-18 | 2018-12-31 | Grünenthal GmbH | Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| KR20150009540A (ko) * | 2012-05-16 | 2015-01-26 | 노파르티스 아게 | Pi-3 키나제 억제제에 대한 투여 요법 |
| RU2668125C2 (ru) * | 2013-03-27 | 2018-09-26 | Тайхо Фармасьютикал Ко., Лтд. | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат |
| KR101847252B1 (ko) * | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| US20160082032A1 (en) * | 2013-05-17 | 2016-03-24 | Taiho Pharmaceutical Co., Ltd. | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| EP3073994A1 (en) | 2013-11-26 | 2016-10-05 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EA201692388A1 (ru) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы |
| BR112017021475A2 (pt) | 2015-04-24 | 2018-07-10 | Gruenenthal Gmbh | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11612653B2 (en) * | 2016-01-08 | 2023-03-28 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator, and antitumor effect potentiator |
| JP6882205B2 (ja) | 2016-02-05 | 2021-06-02 | 大鵬薬品工業株式会社 | 重度腎機能障害を有する癌患者に対する治療方法 |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US20260021045A1 (en) * | 2024-07-17 | 2026-01-22 | Jnd Therapeutics, Inc. | Methods and formulations for treatment of liver cancer using trifluridine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744475A (en) * | 1995-03-29 | 1998-04-28 | Taiho Pharmaceutical Co., Ltd. | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| JP3088758B2 (ja) * | 1996-09-24 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体を含有する癌転移抑制剤 |
| ES2630002T5 (es) | 2005-01-26 | 2024-09-19 | Taiho Pharmaceutical Co Ltd | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
-
2006
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1849470T3 (da) | Anticancerlægemiddel indeholdende alpha, alpha, alpha-trifluorthymidin og thymidinphosphorylaseinhibitor | |
| USRE46284E1 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
| EP1626719A1 (en) | Pharmaceutical composition containing histone deacetylase inhibitor | |
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| KR20090025247A (ko) | 방사선 치료 증강제 | |
| US20090281105A1 (en) | Radiotherapy enhancer | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| ES2644237T3 (es) | Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD | |
| EP2268287B1 (en) | Dosage regimens of an antitumor agent comprising deoxycytidine derivative | |
| JP5066737B2 (ja) | シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤 | |
| JPWO2012105486A1 (ja) | １日１回隔日投与を特徴とするテガフール含有組成物 |